Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD

Vontobel Holding Ltd. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% in the second quarter, Holdings Channel reports. The firm owned 205,293 shares of the biopharmaceutical company’s stock after selling 23,818 shares during the period. Vontobel Holding Ltd.’s holdings in Gilead Sciences were worth $22,761,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GILD. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $215,000. GAMMA Investing LLC lifted its holdings in Gilead Sciences by 24.9% during the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock worth $2,550,000 after buying an additional 4,532 shares during the period. Simplicity Wealth LLC purchased a new stake in Gilead Sciences during the first quarter worth $483,000. Finally, Integrated Advisors Network LLC lifted its holdings in Gilead Sciences by 7.6% during the first quarter. Integrated Advisors Network LLC now owns 8,138 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 574 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $116.74 on Friday. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The stock has a fifty day moving average price of $114.57 and a 200-day moving average price of $110.19. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market cap of $144.85 billion, a PE ratio of 23.26, a P/E/G ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the business posted $2.01 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last quarter. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GILD shares. Cantor Fitzgerald upped their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.